Histamine receptors in GtoPdb v.2023.1

Paul Chazot, Marlon Cowart, Hiroyuki Fukui, C. Robin Ganellin, Ralf Gutzmer, Helmut L. Haas, Stephen J. Hill, Rebecca Hills, Rob Leurs, Roberto Levi, Steve Liu, Pertti Panula, Walter Schunack, Jean-Charles Schwartz, Roland Seifert, Nigel P. Shankley, Holger Stark, Robin Thurmond, Henk Timmerman, J. Michael Young
{"title":"Histamine receptors in GtoPdb v.2023.1","authors":"Paul Chazot, Marlon Cowart, Hiroyuki Fukui, C. Robin Ganellin, Ralf Gutzmer, Helmut L. Haas, Stephen J. Hill, Rebecca Hills, Rob Leurs, Roberto Levi, Steve Liu, Pertti Panula, Walter Schunack, Jean-Charles Schwartz, Roland Seifert, Nigel P. Shankley, Holger Stark, Robin Thurmond, Henk Timmerman, J. Michael Young","doi":"10.2218/gtopdb/f33/2023.1","DOIUrl":null,"url":null,"abstract":"Histamine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Histamine Receptors [80, 174]) are activated by the endogenous ligand histamine. Marked species differences exist between histamine receptor orthologues [80]. The human and rat H3 receptor genes are subject to significant splice variance [12]. The potency order of histamine at histamine receptor subtypes is H3 = H4 > H2 > H1 [174]. Some agonists at the human H3 receptor display significant ligand bias [183]. Antagonists of all 4 histamine receptors have clinical uses: H1 antagonists for allergies (e.g. cetirizine), H2 antagonists for acid-reflux diseases (e.g. ranitidine), H3 antagonists for narcolepsy (e.g. pitolisant/WAKIX; Registered) and H4 antagonists for atopic dermatitis (e.g. adriforant; Phase IIa) [174] and vestibular neuritis (AUV) (SENS-111 (Seliforant, previously UR-63325), entered and completed vestibular neuritis (AUV) Phase IIa efficacy and safety trials, respectively) [217, 8].","PeriodicalId":14617,"journal":{"name":"IUPHAR/BPS Guide to Pharmacology CITE","volume":"74 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IUPHAR/BPS Guide to Pharmacology CITE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2218/gtopdb/f33/2023.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Histamine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Histamine Receptors [80, 174]) are activated by the endogenous ligand histamine. Marked species differences exist between histamine receptor orthologues [80]. The human and rat H3 receptor genes are subject to significant splice variance [12]. The potency order of histamine at histamine receptor subtypes is H3 = H4 > H2 > H1 [174]. Some agonists at the human H3 receptor display significant ligand bias [183]. Antagonists of all 4 histamine receptors have clinical uses: H1 antagonists for allergies (e.g. cetirizine), H2 antagonists for acid-reflux diseases (e.g. ranitidine), H3 antagonists for narcolepsy (e.g. pitolisant/WAKIX; Registered) and H4 antagonists for atopic dermatitis (e.g. adriforant; Phase IIa) [174] and vestibular neuritis (AUV) (SENS-111 (Seliforant, previously UR-63325), entered and completed vestibular neuritis (AUV) Phase IIa efficacy and safety trials, respectively) [217, 8].
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
GtoPdb v.2023.1中的组胺受体
组胺受体(由NC-IUPHAR组胺受体小组委员会商定的命名法[80,174])由内源性配体组胺激活。组胺受体同源物之间存在明显的物种差异[80]。人和大鼠的H3受体基因存在显著的剪接变异[12]。组胺在组胺受体亚型上的效价顺序为H3 = H4 >H2祝辞H1[174]。一些人H3受体激动剂表现出明显的配体偏倚[183]。所有4种组胺受体的拮抗剂都有临床用途:H1拮抗剂用于过敏(如西替利嗪),H2拮抗剂用于酸反流疾病(如雷尼替丁),H3拮抗剂用于发作性睡病(如pitolisant/WAKIX;已注册)和H4拮抗剂用于特应性皮炎(例如:adriforant;IIa期)[174]和前庭神经炎(AUV) (SENS-111 (Seliforant,原UR-63325)分别进入并完成了前庭神经炎(AUV) IIa期疗效和安全性试验)[217,8]。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
E3 ubiquitin ligase components in GtoPdb v.2023.2 Transient Receptor Potential channels (TRP) in GtoPdb v.2023.2 Lanosterol biosynthesis pathway in GtoPdb v.2023.1 Free fatty acid receptors in GtoPdb v.2023.1 Epithelial sodium channel (ENaC) in GtoPdb v.2023.1
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1